FDA fast-tracks new Gleevec use

Earlier this week, Novartis got FDA priority review for Gleevec, its cancer med, for treatment of gastrointestinal stromal tumors after surgery. The agency will say "yea" or "nay" on the new indication within six months, rather than the typical 10. According to Novartis research, Gleevec cut the risk of tumors returning after surgery by 89 percent. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.